ASBP on Nasdaq
Aspire-Lakewood Holdings, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Azitra, Inc., Processa Pharmaceuticals, Inc. or ZIOPHARM Oncology, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 99% of the revenue Aspire-Lakewood Holdings, Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2025 |
|---|---|
| United States | $6.2K |
| Canada | $30 |
| United Kingdoms | $19 |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue1¢$6.3K
- Research and development99¢$923.9K
Out of $6.2K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net revenue | $6.2K | |
| Cost of revenue | $6.3K | |
| Gross margin | -$116 | |
| General and administrative (including stock-based compensation of $14.1 million and $0, respectively) | $17.6M | $940.4K |
| Research and development | $923.9K | $144.4K |
| Sales and marketing | $789.8K | $126.1K |
| Total operating expenses | $19.4M | $1.2M |
| Loss from operations | -$19.4M | -$1.2M |
| Interest expense | -$8.5M | -$98.0K |
| Change in fair value of liabilities | $3.9M | |
| Initial recognition of forward purchase liability | -$95.1K | |
| Loss on extinguishment of debt | -$364.1K | |
| Total other expense, net | -$5.1M | -$98.0K |
| Loss before provision for income taxes | -$24.5M | -$1.3M |
| Income tax expense | -$1.0K | |
| Net loss | -$24.5M | -$1.3M |
| Weighted average shares outstanding of Common Stock, basic | 1.5M shares | 689.9K shares |
| Weighted average shares outstanding of Common Stock, diluted | 1.5M shares | 689.9K shares |
| Earnings Per Share, Diluted | -$16.38 | -$1.90 |
| Stock based compensation | $14.1M | $0 |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2025-02-28 | 2024-12-31 |
|---|---|---|---|
| Cash | $1.0M | $3.6K | |
| Prepaid expenses and other current assets | $55.1K | $144.4K | |
| Inventories | $253.2K | ||
| Total current assets | $1.3M | $148.0K | |
| TOTAL ASSETS | $1.3M | $148.0K | |
| Accounts payable | $1.0M | $310.2K | |
| Accrued expenses | $1.0M | ||
| Other current liabilities | $353.7K | $111.0K | |
| Derivative liability | $41.0K | ||
| Subscription agreement loans | $1.5M | ||
| Convertible note | $1.3M | ||
| Total current liabilities | $7.6M | $1.7M | |
| Forward purchase agreement liability | $95.7K | ||
| TOTAL LIABILITIES | $7.7M | $1.7M | |
| Common stock; $0.0001 par value; 490,000,000 shares authorized; 3,533,408 and 690,044 issued and outstanding at December 31, 2025 and 2024, respectively | $353 | $69 | |
| Additional paid-in capital | $20.9M | $1.2M | |
| Accumulated deficit | -$27.3M | -$2.8M | |
| TOTAL STOCKHOLDERS DEFICIT | -$6.4M | -$1.5M | |
| TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT | $1.3M | $148.0K | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 490.0M shares | 490.0M shares | |
| Common stock, shares issued | 3.5M shares | 690.0K shares | |
| Common stock, shares outstanding | 3.5M shares | 690.0K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$24.5M | -$1.3M |
| Amortization of debt discount | $8.0M | |
| Initial recognition of forward purchase agreement liability | $95.1K | |
| Issuance of commitment shares under ELOC agreement | $275.0K | |
| Loss on extinguishment of debt | $364.1K | |
| Change in fair value of derivative liabilities and convertible notes | -$3.9M | |
| Stock-based compensation | $14.1M | |
| Prepaid expenses and other current assets | $174.3K | -$109.4K |
| Inventories | -$253.2K | |
| Accounts payable | -$323.8K | $247.8K |
| Accrued expenses | $1.0M | |
| Due to related party | $906.2K | |
| Other current liabilities | -$111.0K | |
| NET CASH FLOWS USED IN OPERATING ACTIVITIES | -$4.9M | -$265.2K |
| Issuance of common stock | $257.6K | |
| Proceeds from recapitalization | $265.8K | |
| Proceeds from issuance of convertible notes | $10.2M | |
| Repayment of convertible notes | -$3.0M | |
| Transaction costs paid in connection with convertible notes | -$907.5K | |
| Proceeds from notes payable - related party | $50.0K | |
| Repayment of notes payable related party | -$701.9K | |
| NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES | $5.9M | $257.6K |
| NET CHANGE IN CASH | $1.0M | -$7.5K |
| Accounts payable and other liabilities combined, net | $4.9M | |
| Shares issued pursuant to settlement agreement | $317.2K | |
| Issuance of shares in reverse recapitalization | $4.6M | |
| Conversion of warrants | $14 | |
| Conversion of convertible notes | $9.5M | |
| Issuance of shares under working capital loans and non redemption agreements | $14 | |
| Cash paid for interest | $44.4K |
Former names
Recent filings
- Sep 29, 20268-K
- Sep 9, 20268-K
- Sep 8, 20268-K
- Aug 19, 20268-K
- Aug 14, 2026SCHEDULE 13G/A
- Aug 13, 202610-Q
- Aug 10, 20268-K
- Aug 10, 2026SCHEDULE 13G
- Aug 6, 2026SCHEDULE 13G/A
- Jul 20, 20268-K
- Jul 2, 2026SCHEDULE 13G
- Jun 22, 20268-K
- Jun 12, 20268-K
- Jun 12, 20268-K
- May 15, 2026SCHEDULE 13G
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8